Skip to main content Accessibility help
×
Home
  • Print publication year: 2012
  • Online publication date: July 2012

Chapter 1 - History of CNS drug development

References

Ayd, J. F. (Ed.) (1980). Haloperidol Update: 1958–1980. Baltimore: Ayd Medical Communications.
Becker, R. E. and Greig, N. H. (2008). Alzheimer's disease drug development in 2008 and beyond: problems and opportunities. Curr Alzheimer Res, 5, 346–57.
Bradford, L. D. (2002). CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics, 3, 229–43.
Brink, C. J. (2010). [Phenobarbital]. Tijdschr Diergeneeskd, 135, 248; author reply 248–9.
Chico, L. K., Van Eldik, L. J., and Watterson, D. M. (2009). Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov, 8, 892–909.
Cummings, J. L. (2008). Controversies in Alzheimer's disease drug development. Int Rev Psychiatry, 20, 389–95.
Darling, H. F., Kruse, W., Hess, G. F., and Hoermann, M. G. (1959). Preliminary study of isocarboxazid, an iproniazid analog. Dis Nerv Syst, 20, 269–71.
Demain, A. L. and Sanchez, S. (2009). Microbial drug discovery: 80 years of progress. J Antibiot (Tokyo), 62, 5–16.
Demuth, G. W. and Ackerman, S. H. (1983). alpha-Methyldopa and depression: a clinical study and review of the literature. Am J Psychiat, 140, 534–8.
Geddes, A. (2008). 80th Anniversary of the discovery of penicillin. An appreciation of Sir Alexander Fleming. Int J Antimicrob Agents, 32, 373.
Gilbert, J., Henske, P., and Singh, A. (2003). Rebuilding Big Pharma's Business Model. IN VIVO The Business & Medicine Report. Winhover Information Inc.
Goodwin, D. W. and Preskorn, S. H. (1982). DSM-III and pharmacotherapy. In Turner, S. and Hersen, M. (Eds.), Adult Psychopathology: A Social Work Perspective. New York: John Wiley and Sons.
Google (2010). Early history of amphetamine – Google Search. Google.
http://itech.dickinson.edu/chemistry/?p=497 (2008). History of Diazepam. The Role of Chemistry in History.
Huh, J., Delorme, D. E., Reid, L. N., and An, S. (2010). Direct-to-consumer prescription drug advertising: history, regulation, and issues. Minn Med, 93, 50–2.
Iversen, L. L., Iversen, S. D., and Snyder, S. H. (Eds.) (1975). Handbook of Psychopharmacology. New York: Plenum Press.
Kaelin, W. G., Jr. (1999). Choosing anticancer drug targets in the postgenomic era. J Clin Invest, 104, 1503–6.
Keefer, C. S. (1970). Alfred Newton Richards in Washington as Chairman of the World War 2 Committee on Medical Research, he brought penicillin from the test tube to full production. Med Aff, 32, 8–11 passim.
Lai, C. W. (2006). Pharmacogenomics: methods and protocols. Brit J Cancer, 94, 1553.
Ligon, B. L. (2004). Penicillin: its discovery and early development. Semin Pediatr Infect Dis, 15, 52–7.
Lopez-Munoz, F. and Alamo, C. (2009). Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des, 15, 1563–86.
Lopez-Munoz, F., Alamo, C., Cuenca, E., Shen, W. W., Clervoy, P., and Rubio, G. (2005). History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiat, 17, 113–35.
Markou, A., Chiamulera, C., Geyer, M. A., Tricklebank, M., and Steckler, T. (2009). Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology, 34, 74–89.
Maxwell, R. A. and Eckhardt, S. B. (2009). Drug Discovery: A Casebook and Analysis. New York: Springer.
Moncrieff, J. (2008). The creation of the concept of an antidepressant: an historical analysis. Soc Sci Med, 66, 2346–55.
Norn, S., Kruse, P. R., and Kruse, E. (2005). [History of opium poppy and morphine]. Dan Medicinhist Arbog, 33, 171–84.
Preskorn, S. H. (1990). The future and psychopharmacology: potentials and needs. Psychiat Ann, 20, 625–33.
Preskorn, S. H. (1996). Clinical Pharmacology of Selective Serotonin Reuptake. Caddo, OK: Professional Communications Inc.
Preskorn, S. H. (2001). Antipsychotic drug development in the pre-human-genome era: a full circle. J Psychiatr Pract, 7, 209–13.
Preskorn, S. H. (2007). The evolution of antipsychotic drug therapy: reserpine, chlorpromazine, and haloperidol. J Psychiatr Pract, 13, 253–7.
Preskorn, S. H. (2009a). Results of the STAR*D study: implications for clinicians and drug developers. J Psychiatr Pract, 15, 45–9.
Preskorn, S. H. (2009b). A roadmap to key pharmacologic principles in using antipsychotics: application in clinical practice. J Clin Psychiat, 70, 593–600.
Preskorn, S. H. and Irwin, H. A. (1982). Toxicity of tricyclic antidepressants – kinetics, mechanism, intervention: a review. J Clin Psychiat, 43, 151–6.
Prien, R. F., Caffey, E. M., Jr., and Klett, C. J. (1971). Lithium carbonate. A survey of the history and current status of Lithium in treating mood disorders. Dis Nerv Syst, 32, 521–31.
Pritchard, J. F. (2008). Risk in CNS drug discovery: focus on treatment of Alzheimer's disease. BMC Neurosci, 9 Suppl 3, S1.
Richards, A. N. (1964). Production of penicillin in the United States (1941–1946). Nature, 201, 441–5.
Seeman, P. (2002). Atypical antipsychotics: mechanism of action. Can J Psychiat, 47, 27–38.
Steinmetz, K. L. and Spack, E. G. (2009). The basics of preclinical drug development for neurodegenerative disease indications. BMC Neurol, 9 Suppl 1, S2.
Stitzel, R. E. (1976). The biological fate of reserpine. Pharmacol Rev, 28, 179–208.
Tost, H., Alam, T., and Meyer-Lindenberg, A. (2010). Dopamine and psychosis: theory, pathomechanisms and intermediate phenotypes. Neurosci Biobehav Rev, 34, 689–700.
Weiden, P. J., Preskorn, S. H., Fahnestock, P. A., Carpenter, D., Ross, R., and Docherty, J. P. (2007). Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a Roadmap. J Clin Psychiat, 68 Suppl 7, 1–48.
www.egonzehnder.com/global/download/issue1bigpharma.pdf (2008). Big Pharma's New Leadership Models: Making them work. Egon Zehnder International.